---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-26-000055"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2026-05-15T11:43:39+00:00"
generated_at: "2026-05-15T11:45:20.143491+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immuneering Q1 net loss $13.5M; cash $198.6M; Phase 3 pancreatic trial recruiting; ASCO data June 1

## Summary
- Q1 2026 net loss $13.5M ($0.21 per share) vs $15.0M ($0.42 per share) in Q1 2025.
- Cash, equivalents and marketable securities $198.6M (Dec 31, 2025: $217.0M); runway into 2029.
- R&D expenses $10.6M (down from $11.5M YoY); G&A expenses $4.7M (up from $4.0M).
- Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer now recruiting; first patient dosing mid-2026.
- Updated survival data from Phase 2a cohort (55 patients) to be presented in oral session at ASCO June 1, 2026.

## SEC filing metadata
- accession: 0001790340-26-000055
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2026-05-15T11:43:39+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034026000055/0001790340-26-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034026000055/imrx-20260515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-26-000055
- JSON: https://secwatch.observer/filing/0001790340-26-000055.json
- Plain text: https://secwatch.observer/filing/0001790340-26-000055.txt

## Key facts
- Earnings Releases
  Immuneering Corp reported the first quarter ended March 31, 2026 results: net income $13.5 million, or $0.21 per share, EPS $0.21 per share.
  - Period: the first quarter ended March 31, 2026
  - Net income: $13.5 million, or $0.21 per share
  - EPS: $0.21 per share
  - Result: reported results
  source text: Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the first quarter ended March 31, 2026, and provided business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1790340/000179034026000055/0001790340-26-000055-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.